Resolute Mining LimitedÂ (ASX: RSG)
Resolute Mining LimitedÂ (ASX: RSG) is engaged in the operations of mining, exploring, developing and production of Gold properties in Australia and Africa. For the year ended 30 June 2018, the company announced revenue from ordinary activities of $445.55 million which is lower than the previous year revenue of $541.18 million. Net profit for the year 2018 was $77.837 million. Net cash flows from operations was $28 million which was $186 million a year ago. Companyâs Diluted earnings per share was 8.72 cents in FY 2018 which was 18.61 cents in 2017. Resolute Mining Limited has recently announced the appointment of Ms. Sabina Shugg as a Non-Executive Director of the company.Â The board has declared a final dividend of 2.0 cents per share. In the last six months the companyâs share price decreased by 17.32% from $1.270 to $1.050 as on 19 September 2018. RSG traded at $1.107 on September 21, 2018 (12 PM AEST).
Evolution Mining Limited (ASX: EVN)
Evolution Mining Limited (ASX: EVN) develops and operates gold related projects in New Zealand and Australia. For the year ended 30 June 2018, the company announced revenue from ordinary activities of $1540.43 million which is 4% higher than the previous year revenue of $1479.88 million. The companyâs statutory profit after tax is $263.4 million in FY 2018 which was 21% higher than $217.6 million of previous year. The EBITDA of the company is $795.1 in FY 2018 which is 11% higher than the previous year. The basic earning per share is 15.57 cents in FY 2018. The company declared a final dividend of 4 cents fully franked which is to be paid at 28 September 2018. The company is expecting to produce more than 700,000 ounces of gold for at least the next three years. Due to investment in major projects at Cowal, the capital expenditure will remain elevated and from fiscal year 2020 onwards it is expected to decline a bit. However, the group has given a healthy outlook for the next three years. In the last six months the companyâs share price decreased by 12.46% from $3.050 to $2.670 as on 19 September 2018. The stock was up 1.4% to $2.890 on September 21, 2018 (12 PM AEST).
Stock Price Volatility (Source: Thomson Reuters)
OceanaGold Corporation (ASX: OGC)Â
OceanaGold Corporation (ASX: OGC) is a gold mining company which is in the business of exploring developing and operating mineral properties in New Zealand, Philippines and the United States. In first half of 2018, the company earned a revenue of $402 million which was $333.5 million a year before. Revenue increased by 20.7% because of higher gold ounces sold, higher average price received for gold and copper and the inclusion of 6 months revenue of the Haile Gold mine. EBITDA in the first half of 2018 was $211 million. The company earned a Net profit of $89 million in the first half FY 2018 which was $61.4 million a year before. The companyâs board declared a dividend of $0.02 per share which was paid on 14 September 2018. The basic and diluted net earning per share is $0.14 per share in H1 2018 compared to $0.10 in H1 2017. In the last six months, the companyâs share price decreased by 12.39%. The stock was down 1.3% to $4.145 on September 21, 2018 (12 PM AEST) while the group lately announced about high-grade mineralisation of gold at the WKP prospect in New Zealand.
WestGold Resources Limited (ASX: WGX)
Up 1.702% on September 21, 2018 (12 PM AEST), WestGold Resources Limited (ASX: WGX) has lately responded to ASX price related query. The group is engaged in the business of exploration, development, mining, and treatment of gold assets primarily in Western Australia. For the year ended 30 June 2018, the company earned a revenue from ordinary activities of $371.6 million which was $307.02 million a year ago. Net loss attributable to members was $1.2 million which was profit of $ 15.8 million a year ago. Net tangible assets per share is $1.12 which was $0.98 million a year ago. Loss before income tax from continuing operations is $54.5 million which was a profit of $10.2 million in the previous year. Groupâs net cash flows from operating activities have been $14.7 million against $75.6 million a year ago. The share price of the company has gone down by 24.19% in the past six months while it is trying to build momentum again. The stock traded at $1.195 as at September 21, 2018 (12 PM AEST).
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a companyâs prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkineâs team of analysts bought you handpicked report for âTop 25 Dividend Stocks For 2018.â
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people.Â Kalkinemedia.comÂ and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
With the pandemic continuing to affect the globe, healthcare companies are evaluating their lead compounds for COVID-19 treatment. Future revenue for these stocks depends on the probability of launching an approved treatment in the market.